<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Cancer Treatment Today &#187; pain</title>
	<atom:link href="http://cancertreatmenttoday.org/tag/pain/feed/" rel="self" type="application/rss+xml" />
	<link>http://cancertreatmenttoday.org</link>
	<description>Knowledge is Power</description>
	<lastBuildDate>Fri, 24 Apr 2026 13:10:44 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Flector patch for cancer pain</title>
		<link>http://cancertreatmenttoday.org/flector-patch-for-cancer-pain/</link>
		<comments>http://cancertreatmenttoday.org/flector-patch-for-cancer-pain/#comments</comments>
		<pubDate>Fri, 08 Mar 2013 12:51:21 +0000</pubDate>
		<dc:creator>M Levin, MD</dc:creator>
				<category><![CDATA[Layperson]]></category>
		<category><![CDATA[cancer pain]]></category>
		<category><![CDATA[Flector]]></category>
		<category><![CDATA[liver damage]]></category>
		<category><![CDATA[pain]]></category>
		<category><![CDATA[patch]]></category>
		<category><![CDATA[Voltaren]]></category>

		<guid isPermaLink="false">http://cancertreatmenttoday.org/?p=10834</guid>
		<description><![CDATA[Flector Patch is a topical  non-steroidal(NSAID) drug diclofenac. Diclofenac has antiinflammatory, analgesic, and anti-fever effects. Each FLECTOR® Patch measures approximately 4 inches by 5.5 inches and contains 180-mg of diclofenac. The recommended dose of FLECTOR® Patch is one patch to the most painful area twice a day (12 hours at a time). FLECTOR® Patch should [...]]]></description>
			<content:encoded><![CDATA[<p>Flector Patch is a topical  non-steroidal(NSAID) drug diclofenac. Diclofenac has antiinflammatory, analgesic, and anti-fever effects. Each FLECTOR® Patch measures approximately 4 inches by 5.5 inches and contains 180-mg of diclofenac. The recommended dose of FLECTOR® Patch is one patch to the most painful area twice a day (12 hours at a time). FLECTOR® Patch should be applied to intact or non-damaged skin. Some physicians feel that these patches can be cut into smaller portions but this has not been formally studied.</p>
<p>A meta-analysis in 2004  showed that drugs of this class applied through skin are effective and safe in treating acute painful conditions for 1 week. Whether this is also true of this patc is not known. Flector patch had also been studied for ostearthritis and localized pain of rheumatic conditions.</p>
<p>Flector has not been adequately studied for pain of metastatic cancer. The oral version, Voltaren, allows the morphien dose to be decreased. However, it can cause liver damage. How well it works as a patch for painful metastases has not been studied.  It is not a completely innocuous drug, especially for a cancer patient who is on chemotherapy and more susceptible to side effects, or with possible liver metastases.</p>
<p>For the Professional version see <a href="http://cancertreatmenttoday.org/10831/"><span style="color: #ff0000;">here</span></a></p>
]]></content:encoded>
			<wfw:commentRss>http://cancertreatmenttoday.org/flector-patch-for-cancer-pain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oxycodone &#8211; pro</title>
		<link>http://cancertreatmenttoday.org/oxycodone-pro/</link>
		<comments>http://cancertreatmenttoday.org/oxycodone-pro/#comments</comments>
		<pubDate>Sun, 16 Sep 2012 16:26:50 +0000</pubDate>
		<dc:creator>M Levin, MD</dc:creator>
				<category><![CDATA[Professional]]></category>
		<category><![CDATA[Supportive Care]]></category>
		<category><![CDATA[bone emtastses]]></category>
		<category><![CDATA[cancer pain]]></category>
		<category><![CDATA[Ocycontin]]></category>
		<category><![CDATA[Oxycodon]]></category>
		<category><![CDATA[pain]]></category>
		<category><![CDATA[Pain management]]></category>
		<category><![CDATA[prostate cancer]]></category>

		<guid isPermaLink="false">http://cancertreatmenttoday.org/?p=8878</guid>
		<description><![CDATA[Oxycodone is a full opioid agonist with no antagonist properties whose principal therapeutic action is analgesia. It has an affinity for kappa, mu and delta opiate receptors in the brain and spinal cord. Oxycodone is similar to morphine in its action. Other pharmacological actions of oxycodone are in the CNS (respiratory depression, antitussive, anxiolytic, sedative [...]]]></description>
			<content:encoded><![CDATA[<p>Oxycodone is a full opioid agonist with no antagonist properties whose principal therapeutic action is analgesia. It has an affinity for kappa, mu and delta opiate receptors in the brain and spinal cord. Oxycodone is similar to morphine in its action. Other pharmacological actions of oxycodone are in the CNS (respiratory depression, antitussive, anxiolytic, sedative and miosis), smooth muscle (constipation, reduction in gastric, biliary and pancreatic secretions, spasm of sphincter of Oddi and transient elevations in serum amylase) and cardiovascular system (release of histamine and/or peripheral vasodilation, possibly causing pruritus, flushing, red eyes, sweating and/or orthostatic hypotension).</p>
<p>OXYCONTIN tablets should be taken at 12-hourly intervals. The dosage is dependent on the severity of the pain, and the patient&#8217;s previous history of analgesic requirements. Increasing severity of pain will require an increased dosage of OXYCONTIN tablets using the 5mg, 10mg, 20mg, 40mg or 80mg tablet strengths, either alone or in combination, to achieve pain relief. The correct dosage for any individual patient is that which controls the pain and is well tolerated, for a full 12 hours. There is no ceiling dose and so patients should be titrated to pain relief unless unmanageable adverse medicine reactions prevent this. The usual starting dose for opioid naïve patients or patients presenting with severe pain uncontrolled by weaker opioids is 10mg 12 hourly, or 5mg 12 hourly for patients with renal or hepatic impairment. The dose should then be carefully titrated, as frequently as once a day if necessary, to achieve pain relief. It is not uncommon for a patient to require higehr doses.</p>
<p>Riley J, Eisenberg E, Müller-Schwefe G, Drewes AM, Arendt-Nielsen L. Oxycodone: a review of its use in the management of pain.Curr Med Res Opin. 2008 Jan;24(1):175-92.</p>
<p>Oxycodone: Pharmacological profile and clinical data in chronic pain management minervamedica.it. Minerva Anestesiologica, 2005;71:451-60.</p>
<p>Management of cancer pain. In VT DeVita Jr et al., eds., Cancer: Principles and Practices of Oncology, 6th ed., pp. 2977–3011. Philadelphia: Lippincott Williams and Wilkins.</p>
<p>Pergolizzi J, Boger R, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organisation step III opioids (Buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone. Pain Pract 2008;8(4):287-313.</p>
<p>Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010;13:401-35.</p>
]]></content:encoded>
			<wfw:commentRss>http://cancertreatmenttoday.org/oxycodone-pro/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
